Ahrens Investment Partners’s Beam Therapeutics BEAM Stock Holding History

Ahrens Investment Partners’s Portfolio BEAM Stock Details BEAM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	$15.3K	Buy	+500	New	+$19.7K	0.01%	526

Other funds holding BEAM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

MWG Management Road Town, Tortola, British Virgin Islands $81.3M AUM 2.28% 1-Year Est. Return

Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ahrens Investment Partners's BEAM Position: Q1 2023 in Review

Ahrens Investment Partners opened a new position in Beam Therapeutics (BEAM) in Q1 2023: 500 shares worth $15.3K. The stake represents 0.01% of the portfolio and ranks #526 among its holdings.

206 funds tracked by Wall St. Rank hold BEAM as of Q1 2023.

Ahrens Investment Partners held 500 shares of Beam Therapeutics worth $15.3K as of Q1 2023.
Beam Therapeutics was a new Ahrens Investment Partners position in Q1 2023.
Beam Therapeutics made up 0.01% of Ahrens Investment Partners's portfolio in Q1 2023, its #526 holding.
206 funds tracked by Wall St. Rank held Beam Therapeutics as of Q1 2023.

Based on Ahrens Investment Partners's 13F filing for Q1 2023, filed 24 Apr 2023.